When comparing the KRAS G12C vs. KRAS non-G12C mutation outcomes in NSCLC across various chemotherapies, there was no difference in the patients who received first-line platinum-based chemotherapy in three multi-variate KRAS mutant analyses [34,35,36]. Here, KRAS is linked to non-small cell lung carcinoma.